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Abstract
Background: There is an urgent need to more accurately diagnose HIV-associated neurocognitive disorder (HAND)
in Africa. Rapid screening tests for HIV-associated dementia are of limited utility due to variable sensitivity and
specificity. The use of selected neuropsychological tests is more appropriate, but norms for HIV seronegative
people are not readily available for sub-Saharan African populations. We sought to derive normative scores for two
commonly used neuropsychological tests that generate four test scores – namely the Trail-Making Test (Parts A
and B) and the Digit Span Test [Forward (DSF) and Backward (DSB)]. To assess memory and recall, we used the
memory item of the International HIV Dementia Scale (IHDS).
Findings: One hundred and ten HIV seronegative participants were assessed at McCord Hospital, Durban, South
Africa between March 3
rd and October 31
st, 2008. We excluded people with major depressive disorder, substance
use abuse and dependence and head injuries (with or without loss of consciousness). All the participants in this
study were African and predominantly female with an average age of 28.5 years and 10 years of education. Age
and gender influenced neuropsychological functioning, with older people performing worse. The effect of gender
was not uniform across all the tests.
Conclusion: These two neuropsychological tests can be administered with the IHDS in busy antiretroviral clinics.
Their performance can be measured against these norms to more accurately diagnose the spectrum and
progression of HAND.
Introduction
Infection of the central nervous system by the human
immunodeficiency virus (HIV) is frequently associated
with potentially debilitating forms of neurocognitive dis-
orders. HIV-associated dementia (HAD) occurs in
approximately 10-15% of all individuals with HIV/AIDS
and is more common in late stages of infection[1]. The
less severe disorder (mild neurocognitive disorder
(MND) and sub-clinical neurocognitive impairment
more common, occurring in 30-60% of people infected
with HIV depending on disease stage [2,3]. Collectively,
these disorders are referred to as HIV-associated neuro-
cognitive disorders (HAND) [4].
While neuropsychological (NP) test batteries are
regarded as the gold standard by which to diagnose
HAND, particularly HAD [5-8], these are not always
available or appropriate in busy clinical settings. It is
important to detect HAD because of its severity despite
a greater than 40% decline in the incidence of HAD
[2,9] since the widespread introduction of highly active
anti-retroviral therapy (HAART). Without antiretroviral
(ARV) therapy, death may ensue within 6 months [10].
South Africa and other sub-Saharan countries follow the
WHO guidelines for initiating ARVs in resource con-
strained settings. People with HAD are eligible to
HAART, regardless of CD4 cell count. In addition to
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HAART on this context, there is growing evidence that
MND and sub-clinical neurocognitive impairment
should also be diagnosed and treated[2].
Many screening tests have been used to detect HAD,
such as the HIV dementia scale (HDS) [6], the EXIT
interview [11], mental alternation tests [12], the modi-
fied Memorial Sloan-Kettering scale [13], and the Inter-
national HIV Dementia Scale [8]. These tools may have
limited clinical utility because they are insensitive to the
milder end of the spectrum of HIV-associated neurocog-
nitive impairment [14]. Longer NP batteries require
local normative data for comparison. Ultimately, a bal-
ance needs to be found between longer but less practical
batteries, and shorter, but less sensitive ones.
The American Academy of Neurology research
nomenclature and diagnostic process for HAND have
recently been updated [4]. This approach not only speci-
fies the domains most affected by HIV, namely speed of
processing information, memory, attention/concentra-
tion, learning, executive functioning, motor and psycho-
motor speed but also requires that specialised NP test
batteries are employed. The administration of detailed
batteries tends to be restricted to research settings, and
requires trained neuropsychologists. In order to address
the gap between longer NP batteries and the brief
screening tools, selected NP tests, which represent the
domains most affected by HIV infection, need to be
identified for use in international settings. In addition,
these tests need to be measured against normative data
obtained from HIV seronegative people in the popula-
tion in question. For example, there is some concern
that “speed” in completing cognitive tests is not empha-
sized equally across regions of the world. If true, healthy
controls outside of US and Europe would perform more
poorly on tests of neurocognitive or motor speed when
compared to normative data obtained in the US or Eur-
ope, where most neurocognitive tests have been devel-
oped [15].
Published norms for neurocognitive tests cannot be
used in all populations. For example, a comparison of
normative scores for the Trail Making Test from various
countries and cultures showed that scores are not
equivalent and can lead to serious diagnostic errors[16].
Relevant to the current study, population normative
scores are not widely available for Africans [7]. Three
quarters of all people living with AIDS live in sub-
Saharan Africa [17]. South Africa is the country with
the highest number of HIV infections worldwide and is
a region where HIV-1 clade C is predominant. While it
has been proposed that clade C was less neurovirulent
than other, better studied clades (like B), it has recently
been suggested that neurocognitive impairment occurs
at similar rates. There are no guidelines to assess
HAND in Africa; yet, the importance is very high from
both clinical and research perspectives as both rely on
normative data to generate clinical classifications of
impairment. The purpose of this study was to establish
population normative scores for a select number of NP
tests that can be used in South African antiretroviral
clinics to assess the neurocognitive domains most com-
monly affected by HIV infection.
Methods
Sample and setting
This study was conducted at McCord Hospital, Durban,
South Africa between March 3
rd and October 31
st, 2008.
McCord Hospital has a voluntary counselling and test-
ing clinic (VCT) for HIV and an ARV clinic. At the
VCT clinic from January th r o u g hD e c e m b e r ,2 0 0 8 ,a
total of 1,052 patients received voluntary counselling
and testing. HIV testing is free and confidential and is
available to anyone requesting a test.
Participants were recruit e df r o mt h eV C Tc l i n i c .T o
limit selection bias, we recruited participants on differ-
ent days and selected people from the list of all people
registered for the day using a random numbers list. We
excluded people who were: HIV seropositive, under 18
years of age, who reported a history of any substance
abuse or dependence in the past three months (includ-
ing alcohol), those who reported any past psychiatric
history, or any history of conditions that would affect
neurocognitive function e.g. past head injury (regardless
of loss of consciousness), cerebrovascular accidents, or
seizure disorders. Primary languages of the participants
were either isiZulu or English. After determining elig-
ibility criteria, one hundred and ten consenting partici-
pants were assessed in a private room to minimize
distractions from noise and other operational distrac-
tions in the VCT clinic. This study was reviewed and
approved by the hospital’s research and ethics commit-
tee prior to study initiation.
Measures
NP Test battery
We chose individual tests which were sensitive to
domains affected by HIV infection, could be adminis-
tered by non-psychologists without specialized equip-
ment, and would require no longer than 20 minutes.
Five tests were initially selected; each of the tests
selected have been successfully administered before on
H I Vs e r o p o s i t i v ep e o p l eb u tn o ti nS o u t hA f r i c a
[5,8,18-20].
Attention and concentration was assessed using Digit
Span Forward (DSF) and Digit Span Backwards (DSB).
Digit span tests are frequently used because they are
sensitive measures of both attention and working mem-
ory[16]. Speed of information processing was assessed
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tive Function was assessed by Trail Making Test Part B
(TMT B). The latter two tests also measure psychomo-
tor functions. While the Grooved Pegboard Test (using
the dominant and non-dominant hands) is regularly
used to detect the motor abnormalities in HAND [5,21],
we did not include this measure because it requires
equipment that is not readily available in primary care
clinics. In addition, other NP tests that are significantly
language-based were not included due to differences in
culture. We assessed memory with the four item recall
from the International HIV Dementia Scale [8].
Together, this brief battery takes between 10-15 minutes
to complete.
DS (a psychiatrist trained in the use of the NP tests)
trained a psychologist to administer the NP tests
according to standard guidelines. In the training, the
test-retest reliability between DS and the psychologist
was 0.89.
Data Analysis
To establish which sociodemographic variables were cor-
related with NP test performance, we analyzed multiple
regression models incorporating age, gender and level of
education as independent variables. In this way, we found
that age was correlated with performance on DSB, the
TMT-A and the TMT-B. Gender was correlated with DSB
and the TMT-B. However, level of education was not sig-
nificantly correlated with any of the NP test variables
included here (see Table 1). Accordingly, we stratified the
NP test performance according to age and gender. We
present the descriptive statistics (mean, median, standard
deviation) for the four NP tests and memory recall subtest
(see Table 2). We divided the age into two convenient
categories (30 years and >= 30 years) closest to the med-
ian. To further assess these variables we also present the
skewness and kurtosis of the distributions.
To improve the clinical utility of the data, we present
the one and two standard deviation (SD) scores of the
NP tests as whole numbers. People impaired on TMT
will take longer (i.e. 1 or 2 SD above the mean time taken
to complete the test) and people impaired on the DSF
and DSB will repeat fewer words (i.e. 1 or 2 SD below the
mean number of words correctly repeated). After per-
forming the NP tests, the scores can be referenced from
Table 2 and defined from Table 3 as establishing whether
a patient was in a non-HAD group (this includes asymp-
tomatic HIV neurocognitive impairment and HIV-asso-
ciated mild neurocognitive disorder) or HAD group. For
example, if a participant scored 2 SD away from the
mean on 2 NP tests and there was no evidence of exclu-
sion criteria, he/she would be defined as having HAD.
Results
All the participants in this study were African, and they
were predominantly female (84.9%). They had an aver-
age age of 28.5 (SD = 8.3) years and 10 (SD = 2) years
of education. The age range was limited from 18 to 50
years. The correlation between age and the various tests
are shown in Figure 1. Using tests of the line of best fit,
it was demonstrated that the older adults performed
worse on the NP tests. The effect of gender was not
uniform across all the tests; women performed better
than men on the TMT B and DSB (table 1).
There was no difference between the first and second
SD of the number of items recalled for female partici-
pants; they recalled 3 items. Amongst the men, fewer
items were recalled two SD from the mean. This lack of
variability amongst the women will create a challenge in
classifying women’s performance. For example if a
women scored 2 SD on one other test and recalled 3
items on the memory subtest, she can be classified as
non-HAD or HAD depending if one reads 3 items in
the 1 SD column or 2 SD column respectively.
Discussion
This is the first study to recommend a brief battery of
standardized NP tests and present locally relevant popu-
lation norms to assess HAND in a country at the epi-
center of the HIV pandemic. In particular, these tests
Table 1 Results of linear multiple regression models that included age, sex and education categories in predicting NP
test score outcomes.
DSF P DSB P TMT-A P TMT-B P
Age group
(30-50 = 1)
-0.417
1 0.149 -0.415 0.036 8.385 0.024 15.846 0.009
Sex
(Male = 1)
-0.172 0.632 0.768 0.002 -2.093 0.646 19.041 0.012
Education group
(< = 10 years = 1)
0.155 0.582 0.033 0.862 1.065 0.766 5.885 0.317
1Beta coefficients
DSF: digit span forward
DSB: digit span backward
TMT-A: Trail making test A
TMT-B: Trail making test B
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Page 3 of 7Table 2 Descriptive Statistics for Age, Educational Level, Gender, Memory Item Score, Digit Span Forward, Digit Span
Backward, and the Trail Making Test Parts A and memory item
Statistics
Age Group 18-29 (n = 68) Mean (S.D) Median Minimum - Maximum Skewness Kurtosis 1 SD from mean 2 SD from
mean
Female
Age 23.29 (2.88) 23 18 - 29
memory 3.77 0.47 4 2 4 -2.33 8.09 3 3
DSF 6.50 1.38 6 4 9 0.17 2.30 5 4
DSB 3.63 0.97 3 2 7 1.01 4.18 3 2
TMT-A 40.73 17.41 35 17 93 1.36 4.25 58 76
TMT-B 72.57 25.97 35.5 37 220 3.13 18.29 99 125
Male
Age 22.62 (2.82) 22 19 - 29
memory 3.39 0.55 3.5 2.5 4 -0.16 1.75 3 2
DSF 6.33 1.12 6 4 8 0.70 3.42 5 4
DSB 4.56 0.73 5 3 5 -1.24 3.17 4 3
TMT-A 35.89 8.94 35 21 55 0.67 4.05 45 54
TMT-B 87.78 26.51 77 61 135 0.69 2.11 115 141
Age Group 30-50 (n = 42)
Female
Age 38.39 (5.15) 39 30 - 50
memory 3.66 0.48 4 2 4 -1.46 5.03 3 3
DSF 6.14 1.40 6 4 9 0.40 2.21 5 3
DSB 3.29 0.83 3 2 6 1.35 5.32 3 2
TMT-A 48.54 18.70 50 18 90 0.33 2.38 67 86
TMT-B 89.26 28.42 85 53 180 1.10 4.23 118 146
Male
Age 36 (5.1) 35 29 - 43
memory 3.19 0.96 3.5 1.5 4 -0.83 2.18 2 1
DSF 6.00 1.07 6 5 8 0.75 2.50 5 4
DSB 3.88 0.99 4 3 6 1.19 3.75 3 2
TMT-A 50.00 13.63 53 28 65 -0.43 1.76 64 77
TMT-B 114.25 43.10 103 67 185 0.49 1.83 157 201
Memory Item: the number of words correctly recalled out of four words.
DSF and DSB: the number of items repeated in the correct sequence.
TMT Part A and TMT Part B: the number of seconds taken to complete test.
Table 3 Diagnosis of HAD Versus Absence of HAD Based on Frascati Criteria
Absence of HAD (incorporating MND, ANI, and No NP
Impairment)
HIV-Associated dementia
(HAD)
Level of NP impairment No to mild NP impairment Moderate to severe NP impairment.
Level of Functional Status
Impairment
No to mild impairment in everyday activities; may need help with
complex tasks, able to perform basic Activities of daily living, walks
without assistance.
Moderate to severe impairment in everyday
activities ; needs help with many or most
activities
Number SD below population
norm on neuropsychological
test
1-2: ANI and MND
0-1: No NP Impairment
≥ 2.0
Number of domains impaired ANI and MND: ≥ 2 HAD: ≥ 2 No NP Impairment: 0-1
Exclusion criteria Absence of criteria for delirium or dementia.
Condition cannot be explained by another comorbid condition e.g.
substance use, infections or neuropsychiatric disorder
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sicians and allied health professionals without specia-
lized NP training who work in busy clinical settings.
Further, these NP tests assess the neurocognitive
domains most frequently and earliest affected by HIV
infection. Depending on the frequency and severity of
abnormal NP test scores, it is possible to identify HAD
in a clinical sample. The stratification of the data by age
and gender allows for a more robust interpretation than
the limited data published to date on other sub-Saharan
African populations that provide only a summary mean
and standard deviation[7].
Our findings are consistent with those of other
researchers who have observed that age affects neuro-
cognitive functioning among HIV infected persons espe-
cially on the TMT [16,22]. Several studies have assessed
the relationship between the TMT and sociodemo-
graphic variables such as educational level, gender, and
age. Of all the sociodemographic variables we consid-
ered, age accounted for most of the variance in NP test
performance [23]. Unlike others we did not find a corre-
lation of the TMT with educational level [24,25]. We
believe this may be because our sample size was too
small to detect this correlation or that years of educa-
tion did not accurately reflect educational differences.
The median years of education in our sample was low
(10 years) compared to other samples that had medians
of 12,6 [25] and 16 years [26]. Previously available nor-
mative data are mainly from Caucasian and well-edu-
cated samples [16,21,22,24,25]. Sub-Saharan African
data are highly limited. Normative data for cognitive
tests has recently become available for school children
in Cameroon [27]. Robertson et al [28] have provided
means and standard deviations for DSF, DSB and the
C o l o rT r a i l sT e x ti naU g a n d a np o p u l a t i o n .H o w e v e r ,
noting the confounding effect of age, educational level,
and culture, the use of these summary means could lead
to errors in HAND diagnosis in our population. For
example, the norms on the Color Trails Test are not
comparable to the time taken to complete the TMT.
Our findings support Fernandez and Marcopulos’ con-
clusion that use of cross-cultural data for the TMT will
lead to errors in classification [16]. For example, accord-
ing to the norms published by Tombach (on a Caucasian
population) the average time for an 18-24 year old to
complete the TMT A and B is 22.93 and 48.97 seconds,
respectively [25]. In our sample these same tests would
r e q u i r ea l m o s to n ea n dah a l ft ot w i c et h a ta m o u n to f
time – 38.92 and 70.96 seconds. The limited variability of
the number of items recalled by women would limit the
clinical utility of the memory subtest. For example, if a
woman recalled three items it will be difficult to classify
her performance because three items is the number of
items on both the first and second standard deviation on
this subtest (table 2). We would recommend investigators
use other longer and more sensitive tests to assess verbal
memory e.g., the California Verbal Learning Test II.
The strengths of this study are that we more completely
present the descriptive statistical properties of NP test per-
formance and the results of relevant stratification of data
rather than the summary measures alone. These data can
be used by other investigators in South Africa to standar-
dize their own local NP test data. Given the well docu-
mented influence of age and educational level on
neurocognitive performance [7,24,29], we adjusted for
these co-factors. The ‘normative’ data thus obtained there-
fore may be controlled for variance according to the age
and educational level of the cohort studied. Our sample
was largely represented by young African females. This is
the group is most frequently affected by HIV infection in
sub-Saharan Africa, and, therefore, our data set serves as
an appropriate reference. Our data meet many of the cri-
teria set out by Mitrushina et al. in evaluating the norms
for the TMT [24]. As recommended, we provide a detailed
description of the sample, with inclusion and exclusion
criteria, gender distribution, and descriptive statistical
properties of the NP data obtained [24].
There are several limitations of this study. The sample
size is relatively small. True population norms typically
require at least a thousand people; however, this level of
sampling is very costly. It may require many years
before such data become available. Others have pre-
sented similarly small sample size studies [16,22,30].
The findings may not be generalizable to the entire
population; however, in the absence of NP data on
South Africans, the high burden of HIV disease, and the
urgent need for more refined methods to diagnose
HAND, this study presents data that can be used imme-
diately by primary care clinicians and allied health pro-
fessionals caring for the HIV infected. Other sub-
Saharan counties can also use these data, as they may
well be more comparable than other data derived on
HIV infected persons from predominantly well educated,
high resource, Caucasian countries.
Conclusion
The assessment of neurocognitive status is recom-
mended as standard evaluation for all HIV seropositive
pesons. Notwithstanding the problems of current
screening tests for HIV-associated dementia and the
need for population norms using the new classification
of HAND, this battery of NP tests does offer an alterna-
tive to other screening scales not standardized on this
population and longer NP test batteries. The four NP
tests we recommend to utilize (DSF, DSB, TMT A,
TMT B) can be completed in 15 minutes, require mini-
mal assessor training, and demand no specialized equip-
ment. Primary care clinicians and allied health
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Page 6 of 7professionals caring for the HIV infected should be
trained to use these NP tests and the available norma-
tive reference data. Data like those reported here, will
assist HIV primary care providers to more reliably diag-
nose HAND, monitor its progression, and its response
to therapy (such as CSF-penetrating ARV medications)
without the need to rely upon CD4 cell count and
plasma viral load to make this assessment.
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